Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast

Molecular Endocrinology

Volumn 25, Issue 8, 2011, Pages 1431-1443

  Khan, Gausal A ^a,b   Girish, Gannareddy V ^a   Lala, Neena ^a   di Guglielmo, Gianni M ^a   Lala, Peeyush K ^a  

^a WESTERN UNIVERSITY   (Canada)

^b DEFENCE INSTITUTE OF PHYSIOLOGY AND ALLIED SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 125; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DECIDUA; ENZYME ACTIVATION; EXTRAVILLOUS TROPHOBLAST; FAR WESTERN BLOTTING; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TROPHOBLAST;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, FAR-WESTERN; CATTLE; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DECORIN; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HLA-G ANTIGENS; HUMANS; IMMUNOPRECIPITATION; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TROPHOBLASTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79961009000     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0426     Document Type: Article

References (62)

1. Weber IT, Harrison RW, Iozzo RV 1996 Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 271:31767-31770
2. Iozzo RV 1997 The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32:141-174
3. Fairlie DP, West ML, Wong AK 1998 Towards protein surface mimetics. Curr Med Chem 5:29-62
4. Seidler DG, Dreier R 2008 Decorin and its galactosaminoglycan chain: extracellular regulator of cellular function? IUBMB Life 60: 729-733
5. Goldoni S, Iozzo RV 2008 Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123:2473-2479
6. Svensson L, Heinegård D, Oldberg A 1995 Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J Biol Chem 270:20712-20716
7. Schonherr E, Broszat M, Brandan E, Bruckner P, Kresse H 1998 Decorin core protein fragment Leu155-Val260 interacts with TGF-β but does not compete for decorin binding to type I collagen. Arch Biochem Biophys 355:241-248
8. Yamaguchi Y, Mann DM, Ruoslahti E 1990 Negative regulation of transforming growth fact-β by the proteoglycan decorin. Nature 346:281-284
9. Ständer M, Naumann U, Wick W, Weller M 1999 Transforming growth factor-β and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 296: 221-227
10. Scott PG, McEwan PA, Dodd CM, Bergmann EM, Bishop PN, Bella J 2004 Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan. Proc Natl Acad Sci USA 101:15633-15638
11. Goldoni S, Owens RT, McQuillan DJ, Shriver Z, Sasisekharan R, Birk DE, Campbell S, Iozzo RV 2004 Biologically active decorin is a monomer in solution. J Biol Chem 279:6606-6612
12. Winnemoller M, Schmidt G, Kresse H 1991 Influence of decorin on fibroblast adhesion to fibronectin. Eur J Cell Biol 54:10-17
13. Winnemoller M, Schon P, Vischer P, Kresse H 1992 Interactions between thrombospondin and the small proteoglycan decorin: interference with cell attachment. Eur J Cell Biol 59:47-55
14. Merle B, Durussel L, Delmas PD, Clezardin P 1999 Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 75:538-546
15. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV 1995 De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 92:7016-7020
16. Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K 2001 Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). J Biol Chem 276:40687-40692
17. Xaus J, Comalada M, Cardo M, Valledor AF, Celada A 2001 Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1). Blood 98:2124-2133
18. Xu G, Guimond MJ, Chakraborty C, Lala PK 2002 Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod 67:681-689
19. Kinsella MG, Fischer JW, Mason DP, Wight TN 2000 Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem 275:13924-13932
20. Davies Cde L, Melder RJ, Munn LL, Mouta-Carreira C, Jain RK, Boucher Y 2001 Decorin inhibits endothelial migration and tubelike structure formation: role of thrombospondin-1. Microvasc Res 62:26-42
21. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV 2002 Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21:4765-4777
22. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, Ge R 2005 Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 280:27935-27948
23. Patel S, Santra M, McQuillan DJ, Iozzo RV, Thomas AP 1998 Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells. J Biol Chem 273:3121-3124
24. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I 1999 Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274:4489-4492
25. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, Iozzo RV 2005 Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar en-docytosis. J Biol Chem 280:32468-32479
26. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G, Iozzo RV 2000 Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275: 32879-32887
27. Santra M, Eichstetter I, Iozzo RV 2000 An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275:35153-35161
28. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV 2006 Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281:26408-26418
29. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV 2008 An antimetastatic role for decorin in breast cancer. Am J Pathol 173:844-855
30. Schonherr E, Sunderkotter C, Iozzo RV, Schaefer L 2005 Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 280:15767-15772
31. Fiedler LR, Schonherr E, Waddington R, Niland S, Seidler DG, Aeschlimann D, Eble JA 2008 Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of α2β integrin activity. J Biol Chem 283:17406-17415
32. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Grone HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM 2007 Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. Am J Pathol 170:301-315
33. Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV 2009 Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185:743-754
34. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, Iozzo RV 2010 Decorin antagonizes Met receptor activity and down-regulates β-catenin and Myc levels. J Biol Chem 285: 42075-42085
35. Lala PK, Chakraborty C 2003 Factors regulating trophoblast migration and invasiveness: possible derangements contributing to pre-eclampsia and fetal injury. Placenta 24:575-587
36. Graham CH, Lala PK 1991 Mechanism of control of trophoblast invasion in situ. J Cell Physiol 148:228-234
37. Graham CH, Connelly I, MacDougall JR, Kerbel RS, Stetler-Stevenson WG, Lala PK 1994 Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-β. Exp Cell Res 214:93-99
38. Iacob D, Cai J, Tsonis M, Babwah A, Chakraborty C, Bhattacha-rjee RN, Lala PK 2008 Decorin-mediated inhibition of proliferation and migration of the human trophoblast via different tyrosine kinase receptors. Endocrinology 149:6187-6197
39. Takahashi T, Shibuya M 1997 The 230 kDa mature form of KDR/ Flk-1 (VEGF receptor-2) activates the PLC-7 pathway and partially induces mitotic signals in NIH3T3 fibroblasts 1. Oncogene 14: 2079-2089
40. Cheng Y, Prusoff WH 1973 Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
41. Athanassiades A, Hamilton GS, Lala PK 1998 Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast. Biol Reprod 59:643-654
42. Athanassiades A, Lala PK 1998 Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 19:465-473
43. Fitzpatrick TE, Lash GE, Yanaihara A, Charnock-Jones DS, Mac-donald-Goodfellow SK, Graham CH 2003 Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor. Exp Cell Res 283:247-255
44. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M 1998 A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273-31282
45. Holmes K, Roberts OL, Thomas AM, Cross MJ 2007 Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19:2003-2012
46. Henriksen K, Karsdal M, Delaisse JM, Engsig MT 2003 RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 278:48745-48753
47. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY 2004 Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res 95:364-371
48. Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT, Edwards IJ 2009 Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11:1042-1053
49. Lysiak JJ, Hunt J, Pringle GA, Lala PK 1995 Localization of transforming growth factor β and its natural inhibitor decorin in the human placenta and decidua throughout gestation. Placenta 16: 221-231
50. Lam PM, Po LS, Cheung LP, Haines C 2005 The effect of exogenous estradiol treatment on the mRNA expression of vascular endothelial growth factor and its receptors in cultured human oviduct mucosal cells. J Assist Reprod Genet 22:251-255
51. Tjoa ML, Levine RJ, Karumanchi SA 2007 Angiogenic factors and preeclampsia. Front Biosci 12:2395-2402
52. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS 2008 The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21:279-287
53. Ran S, Huang X, Downes A, Thorpe PE 2003 Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia 5:297-307
54. Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, Khoo N, Lala PK 1993 Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res 206:204-211
55. Nicola C, Timoshenko AV, Dixon SJ, Lala PK, Chakraborty C 2005 EP1 receptor-mediated migration of the first trimester human extravillous trophoblast: the role of intracellular calcium and cal-pain. J Clin Endocrinol Metab 90:4736-4746
56. Zdravkovic M, Aboagye-Mathiesen G, Guimond MJ, Hager H, Ebbesen P, Lala PK 1999 Susceptibility of MHC class I expressing extravillous trophoblast cell lines to killing by natural killer cells. Placenta 20:431-440
57. Kalkunte S, Lai Z, Tewari N, Chichester C, Romero R, Padbury J, Sharma S 2008 In vitro and in vivo evidence for lack of endovas-cular remodeling by third trimester trophoblasts. Placenta 29:871-878
58. Kilburn BA, Wang J, Duniec-Dmuchowski ZM, Leach RE, Romero R, Armant DR 2000 Extracellular matrix composition and hypoxia regulate the expression of HLA-G and integrins in a human trophoblast cell line. Biol Reprod 62:739-747
59. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, Walker JH, Zachary IC, Ponnambalam S 2006 Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic 7:1270-1282
60. Liebler DC 2008 Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol 21:117-128
61. Blackwood EM, Eisenman RN 1991 Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251:1211-1217
62. Bylund DB, Toews ML 1993 Radioligand binding methods: practical guide and tips. Am J Physiol 265:L421-L429